Abstract
High-dose myeloablative therapy with allogeneic hematopoietic transplantation is an effective treatment for hematologic malignancies, but this approach is associated with a high risk of complications. The use of relatively nontoxic, nonmyeloablative, or reduced-intensity preparative regimens still allows engraftment and the generation of graft-vs-malignancy effects, is potentially curative for susceptible malignancies, and reduces the risk of treatment-related morbidity. Two general strategies along these lines have emerged, based on the use of (1) immunosuppressive chemotherapeutic drugs, usually a purine analog in combination with an alkylating agent, and (2) low-dose total body irradiation, alone or in combination with fludarabine (Fludara).
Original language | English (US) |
---|---|
Pages (from-to) | 94-100 |
Number of pages | 7 |
Journal | ONCOLOGY |
Volume | 17 |
Issue number | 1 |
State | Published - Jan 2003 |
ASJC Scopus subject areas
- Oncology
- Cancer Research